Markus Otto

Markus Otto's AcademicInfluence.com Rankings

Markus Otto

Medical

#3453

World Rank

#3921

Historical Rank

Neurology

#316

World Rank

#399

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Markus Otto Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Markus Otto's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Neurofilaments as biomarkers in neurological disorders (2018) (939)
Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia (2015) (637)
Detection of 14‐3‐3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt‐Jakob disease (1998) (436)
Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease (1997) (331)
Guillain–Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases (2020) (284)
Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation (2002) (277)
Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment (2004) (268)
Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease (2002) (266)
Neurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau (2004) (249)
Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt–Jakob disease from other dementias (2003) (243)
Large‐scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease (2001) (224)
Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients (2015) (222)
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease (2019) (212)
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry (2017) (209)
Neurofilament light chain: a biomarker for genetic frontotemporal dementia (2016) (189)
Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. (2019) (187)
TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. (2008) (181)
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial (2013) (178)
Efficacy of flupirtine on cognitive function in patients with CJD (2004) (175)
CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia (2006) (174)
Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis (2015) (174)
Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. (2004) (158)
The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease (2015) (151)
14-3-3 adaptor proteins recruit AID to 5′-AGCT-3′-rich switch regions for class switch recombination (2010) (140)
Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis (2018) (139)
Hot-spot KIF5A mutations cause familial ALS (2018) (136)
Boxing and running lead to a rise in serum levels of S-100B protein. (2000) (129)
Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment. (2019) (129)
Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease (2009) (129)
Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study (2019) (128)
Consensus Paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia (2005) (125)
A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral Sclerosis (2012) (122)
Beta-Amlyoid 1–42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinson’s Disease Dementia (2006) (121)
The Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS) (2010) (121)
Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia (2017) (121)
Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis (2018) (119)
S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease (1997) (113)
Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. (2004) (111)
Serum GFAP as a biomarker for disease severity in multiple sclerosis (2018) (111)
Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases (2014) (111)
International quality control survey of neurochemical dementia diagnostics (2006) (110)
Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer’s disease (2007) (109)
IgG Antibodies against Measles, Rubella, and Varicella Zoster Virus Predict Conversion to Multiple Sclerosis in Clinically Isolated Syndrome (2009) (107)
Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study (2016) (104)
Isoform Pattern of 14‐3‐3 Proteins in the Cerebrospinal Fluid of Patients with Creutzfeldt‐Jakob Disease (1999) (104)
Role of interleukin-1 in prion disease-associated astrocyte activation. (2004) (102)
Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease (2012) (101)
Cerebrospinal fluid amyloid β peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier‐mediated epitope masking of amyloid β peptides (2004) (101)
Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study (2008) (101)
NEK1 mutations in familial amyotrophic lateral sclerosis. (2016) (101)
Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment (2017) (100)
Diagnosis of Creutzfeldt-Jakob disease by two-dimensional gel electrophoresis of cerebrospinal fluid (1996) (99)
The amyloid-β (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Aβ peptide (2003) (99)
The cryo-electron microscopy structure of huntingtin (2018) (98)
The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. (2011) (97)
Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study (2019) (96)
14-3-3 proteins in neurodegeneration. (2011) (92)
Serum Tau Protein Level as a Marker of Axonal Damage in Acute Ischemic Stroke (2002) (88)
Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies (2001) (87)
Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase (2018) (87)
A ferroptosis–based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis (2019) (85)
Tau Protein, Aβ42 and S-100B Protein in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies (2005) (83)
Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. (2014) (83)
Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS (2012) (82)
β‐amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease (2003) (82)
Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease (2016) (81)
Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS (2016) (80)
Amyloid β peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease (2004) (79)
Serum NFL discriminates Parkinson disease from atypical parkinsonisms (2019) (79)
Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression (2017) (78)
Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer′s and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies* (2016) (77)
Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases (2008) (77)
CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia (2019) (76)
Poly‐GP in cerebrospinal fluid links C9orf72‐associated dipeptide repeat expression to the asymptomatic phase of ALS/FTD (2017) (76)
Reporting Cerebrospinal Fluid Data: Knowledge Base and Interpretation Software (2001) (76)
Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia (2020) (75)
Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases (2004) (75)
Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt–Jakob disease (2006) (74)
Cerebrospinal Fluid Immunoglobulin Kappa Light Chain in Clinically Isolated Syndrome and Multiple Sclerosis (2014) (73)
Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. (2000) (73)
[German consortium for frontotemporal lobar degeneration]. (2011) (73)
Mutual exacerbation of peroxisome proliferator‐activated receptor γ coactivator 1α deregulation and α‐synuclein oligomerization (2014) (72)
Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt-Jakob disease. (2009) (70)
Predicting behavioral variant frontotemporal dementia with pattern classification in multi-center structural MRI data (2017) (70)
Total tau protein, phosphorylated tau (181p) protein, β-amyloid1–42, and β-amyloid1–40 in cerebrospinal fluid of patients with dementia with Lewy bodies (2006) (69)
Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer’s disease (2005) (68)
Cerebrospinal fluid‐optimized two‐dimensional difference gel electrophoresis (2‐D DIGE) facilitates the differential diagnosis of Creutzfeldt–Jakob disease (2008) (68)
Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias (2017) (67)
Blood GFAP as an emerging biomarker in brain and spinal cord disorders (2022) (67)
Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia (2018) (67)
Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis? (2017) (67)
Cisternal S100 protein and neuron-specific enolase are elevated and site-specific markers in intractable temporal lobe epilepsy (1999) (67)
Unchanged Survival Rates of 14-3-3γ Knockout Mice after Inoculation with Pathological Prion Protein (2005) (66)
Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis (2014) (66)
Revised McDonald criteria: The persisting importance of cerebrospinal fluid analysis (2011) (65)
Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker? (2019) (65)
Serum Heart-Type Fatty Acid-Binding Protein and Cerebrospinal Fluid Tau: Marker Candidates for Dementia with Lewy Bodies (2007) (65)
TDP‐43 loss of function inhibits endosomal trafficking and alters trophic signaling in neurons (2016) (64)
Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases (2010) (63)
Comprehensive analysis of the mutation spectrum in 301 German ALS families (2018) (63)
CSF diagnosis of Alzheimer’s disease and dementia with Lewy bodies (2006) (62)
Capillary cerebral amyloid angiopathy in Alzheimer’s disease: association with allocortical/hippocampal microinfarcts and cognitive decline (2018) (61)
Serum neurofilament light chain in behavioral variant frontotemporal dementia (2018) (60)
iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia (2012) (60)
Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. (2019) (56)
Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net (2017) (55)
Decreased IL-8 levels in CSF and serum of AD patients and negative correlation of MMSE and IL-1β (2016) (55)
Cerebrospinal Fluid Tau, p-Tau 181 and Amyloid-β38/40/42 in Frontotemporal Dementias and Primary Progressive Aphasias (2010) (54)
Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis (2008) (54)
Blood‐based neurochemical diagnosis of vascular dementia: a pilot study (2007) (53)
Clinical implications of nucleic acid amplification methods for the diagnosis of viral infections of the nervous system. (1996) (52)
Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies. (2006) (51)
Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. (2007) (50)
Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. (2019) (50)
Proteome Profiling in Murine Models of Multiple Sclerosis: Identification of Stage Specific Markers and Culprits for Tissue Damage (2009) (49)
Electrophoretic separation of amyloid β peptides in plasma (2004) (49)
Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias (2007) (48)
Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls (2018) (48)
Miller‐Fisher syndrome after COVID‐19: neurochemical markers as an early sign of nervous system involvement (2020) (48)
Distinct molecular patterns of TDP-43 pathology in Alzheimer’s disease: relationship with clinical phenotypes (2020) (47)
Increased Levels of Antigen-Bound β-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer’s Disease Patients (2013) (47)
Water-soluble allyl sulfones for dual site-specific labelling of proteins and cyclic peptides† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c6sc00005c (2016) (45)
Protein biomarkers in Parkinson's disease: Focus on cerebrospinal fluid markers and synaptic proteins (2016) (44)
Kinetics of Serum Neuron‐Specific Enolase and Prolactin in Patients After Single Epileptic Seizures (1999) (44)
Diagnosis of Creutzfeldt-Jakob disease and related human spongiform encephalopathies. (1997) (44)
Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. (2008) (44)
AADvac1, an Active Immunotherapy for Alzheimer’s Disease and Non Alzheimer Tauopathies: An Overview of Preclinical and Clinical Development (2018) (43)
Normal hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with Huntington's disease (2005) (43)
Soluble Beta-Amyloid Precursor Protein Is Related to Disease Progression in Amyotrophic Lateral Sclerosis (2011) (43)
Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. (2003) (43)
Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis (2019) (43)
The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide. (2003) (42)
Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. (2005) (42)
Fluid biomarkers in frontotemporal dementia: past, present and future (2020) (40)
Differential pattern of brain‐specific CSF proteins tau and amyloid‐beta in Parkinsonian syndromes (2010) (40)
Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German–Austrian retrospective multicenter study in patients with a clinically isolated syndrome (2016) (40)
Specific 14-3-3 isoform detection and immunolocalization in prion diseases. (2001) (39)
Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldt–Jakob disease (2010) (39)
Cerebrospinal fluid analyses for the diagnosis of subarachnoid haemorrhage and experience from a Swedish study. What method is preferable when diagnosing a subarachnoid haemorrhage? (2013) (39)
Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia (2020) (38)
White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation (2018) (38)
Microchip electrophoresis profiling of Aβ peptides in the cerebrospinal fluid of patients with Alzheimer's disease. (2010) (37)
Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen (2019) (37)
Predicting primary progressive aphasias with support vector machine approaches in structural MRI data (2017) (36)
Biomarkers for diseases with TDP-43 pathology (2019) (36)
Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen (2019) (35)
Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients – An Atlas-Based Volumetric MRI Study (2018) (35)
Simultaneous analysis by capillary electrophoresis of five amyloid peptides as potential biomarkers of Alzheimer's disease. (2008) (35)
Tauopathies and synucleinopathies: Do cerebrospinal fluid β-amyloid peptides reflect disease-specific pathogenesis? (2007) (35)
Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis. (2008) (34)
Analysis of amyloid-β peptides in cerebrospinal fluid samples by capillary electrophoresis coupled with LIF detection. (2011) (34)
A Review on MS-Based Blood Biomarkers for Alzheimer’s Disease (2019) (34)
Intact protein analysis of ubiquitin in cerebrospinal fluid by multiple reaction monitoring reveals differences in Alzheimer's disease and frontotemporal lobar degeneration. (2014) (33)
Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment (2019) (33)
Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease. (2020) (33)
An integrated microfluidic chip for immunocapture, preconcentration and separation of β-amyloid peptides. (2015) (32)
Tau, Phospho-Tau, and S-100B in the Cerebrospinal Fluid of Children With Multiple Sclerosis (2005) (32)
Decrease of S100 beta protein in serum of patients with amyotrophic lateral sclerosis (1998) (32)
Mutual exacerbation of PGC-1α deregulation and α-synuclein oligomerization (2015) (32)
Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach (2018) (32)
Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinson’s Disease Dementia (2012) (31)
Clinical and differential diagnosis of Creutzfeldt-Jakob disease. (2000) (31)
CHCHD10 mutations p.R15L and p.G66V cause motoneuron disease by haploinsufficiency (2018) (31)
Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia (2021) (30)
Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia (2019) (30)
Development of a magnetic immunosorbent for on-chip preconcentration of amyloid β isoforms: Representatives of Alzheimer's disease biomarkers. (2012) (30)
Neurochemical Approaches in the Laboratory Diagnosis of Parkinson and Parkinson Dementia Syndromes: A Review (2009) (30)
CSF Free Light Chains as a Marker of Intrathecal Immunoglobulin Synthesis in Multiple Sclerosis: A Blood-CSF Barrier Related Evaluation in a Large Cohort (2019) (30)
Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. (2004) (29)
A Modified Reading the Mind in the Eyes Test Predicts Behavioral Variant Frontotemporal Dementia Better Than Executive Function Tests (2018) (29)
Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression (2017) (28)
Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia (2021) (28)
Neuroprotective function of cellular prion protein in a mouse model of amyotrophic lateral sclerosis. (2010) (28)
Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update (2016) (27)
Electrophoretic separation of amyloid beta peptides in plasma. (2004) (27)
Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis (2017) (27)
Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration (2021) (26)
Mass spectrometry imaging (MSI) of metals in mouse spinal cord by laser ablation ICP-MS. (2012) (26)
Differential early subcortical involvement in genetic FTD within the GENFI cohort (2021) (26)
Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer’s disease (2020) (26)
Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies (2017) (26)
Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40ox% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia (2010) (25)
Effect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis (2020) (25)
cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases (2010) (25)
CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease. (2011) (25)
Dysregulation of a novel miR-1825/TBCB/TUBA4A pathway in sporadic and familial ALS (2018) (25)
Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia (2019) (25)
Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration (2009) (25)
Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: Current status and future perspectives. (2015) (24)
Elevated Serum Levels of Astroglial S100β in Patients with Liver Cirrhosis Indicate Early and Subclinical Portal-Systemic Encephalopathy (1999) (24)
Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD (2016) (24)
CSF Concentrations of cAMP and cGMP Are Lower in Patients with Creutzfeldt-Jakob Disease but Not Parkinson's Disease and Amyotrophic Lateral Sclerosis (2012) (24)
2D DIGE of the cerebrospinal fluid proteome in neurological diseases (2010) (24)
White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study (2019) (24)
Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort (2020) (23)
Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS (2021) (23)
Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 hexanucleotide repeat expansion (2020) (23)
Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes (2020) (22)
Story of the ALS-FTD continuum retold: rather two distinct entities (2018) (22)
FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations (2019) (22)
Comparison of Internal Standard Approaches for SRM Analysis of Alpha-Synuclein in Cerebrospinal Fluid. (2018) (22)
Modified serpinA1 as risk marker for Parkinson’s disease dementia: Analysis of baseline data (2016) (22)
Creutzfeldt–Jakob disease and oxidative stress (2000) (21)
Education modulates brain maintenance in presymptomatic frontotemporal dementia (2019) (21)
Serum neurofilament light chain (2020) (21)
Online Preconcentration in Capillaries by Multiple Large-Volume Sample Stacking: An Alternative to Immunoassays for Quantification of Amyloid Beta Peptides Biomarkers in Cerebrospinal Fluid. (2018) (21)
CSF amyloid‐β 1‐38 and 1‐42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction (2008) (20)
Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration (2020) (20)
Intrathecal immunoglobulin M production: A promising high‐risk marker in clinically isolated syndrome patients (2018) (19)
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study (2022) (19)
Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis? (2015) (19)
Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia (2016) (19)
Follow-Up Investigations of Tau Protein and S-100B Levels in Cerebrospinal Fluid of Patients with Creutzfeldt-Jakob Disease (2005) (19)
CSF Lactate Dehydrogenase Activity in Patients with Creutzfeldt-Jakob Disease Exceeds That in Other Dementias (2004) (19)
A Proteomic Approach for the Diagnosis of Bacterial Meningitis (2010) (18)
Different CSF β-amyloid processing in Alzheimer’s and Creutzfeldt–Jakob disease (2011) (18)
Lithium Decreases Secretion of Aβ1–42 and C-Truncated Species Aβ1–37/38/39/40 in Chicken Telencephalic Cultures but Specifically Increases Intracellular Aβ1–38 (2004) (18)
VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies (2019) (18)
Quantifying amyloid fibrils in protein mixtures via infrared attenuated-total-reflection spectroscopy (2015) (18)
Differential diagnosis of neurodegenerative diseases with special emphasis on Creutzfeldt-Jakob disease. (2003) (17)
Atrophy and structural covariance of the cholinergic basal forebrain in primary progressive aphasia (2016) (17)
Diagnostic problems during late course in Creutzfeldt-Jakob disease (2003) (17)
A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort (2020) (17)
Neurochemical biomarkers in amyotrophic lateral sclerosis. (2019) (16)
A Score Based on NfL and Glial Markers May Differentiate Between Relapsing–Remitting and Progressive MS Course (2020) (16)
Quantifying progression in primary progressive aphasia with structural neuroimaging (2021) (15)
CSF SerpinA1 in Creutzfeldt–Jakob disease and frontotemporal lobar degeneration (2020) (15)
Upregulation of CRABP1 in human neuroblastoma cells overproducing the Alzheimer-typical Aβ42 reduces their differentiation potential (2008) (15)
S1 guidelines “lumbar puncture and cerebrospinal fluid analysis” (abridged and translated version) (2020) (15)
Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia (2019) (15)
Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers (2020) (15)
Exacerbation of chronic inflammatory demyelinating polyneuropathy in concomitance with COVID-19 (2020) (14)
CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer’s disease (2019) (14)
Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen (2019) (14)
Longitudinal Diffusion Tensor Imaging Resembles Patterns of Pathology Progression in Behavioral Variant Frontotemporal Dementia (bvFTD) (2018) (14)
Glial fibrillary acidic protein as blood biomarker for differential diagnosis and severity of major depressive disorder. (2021) (14)
Analysis of early death based on the prediction model in Wegener's granulomatosis with pulmonary and renal involvement. (2007) (14)
Aggregated α-Synuclein Increases SOD1 Oligomerization in a Mouse Model of Amyotrophic Lateral Sclerosis. (2016) (14)
Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia (2011) (14)
Capillary isoelectric focusing immunoassay as a new nanoscale approach for the detection of oligoclonal bands (2015) (13)
Necrosome‐positive granulovacuolar degeneration is associated with TDP‐43 pathological lesions in the hippocampus of ALS/FTLD cases (2020) (13)
Influence of the blood‐CSF‐barrier function on S100B in neurodegenerative diseases (2013) (13)
CSF amyloid-b-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia (2006) (13)
Aβ peptide1–42, Tau protein and S-100B protein level in cerebrospinal fluid of three patients with primary progressive aphasia (2002) (13)
Elevated levels of serum S100 beta protein in scrapie hamsters. (1998) (12)
Proteomic Analysis of the Cerebrospinal Fluid of Patients with Creutzfeldt-Jakob Disease (2006) (12)
S100B in the cerebrospinal fluid—A marker for glial damage in the rabbit model of pneumococcal meningitis (2010) (12)
Late increase of serum S100 beta protein levels in hamsters after oral or intraperitoneal infection with scrapie. (1999) (12)
Longitudinal Serum Neurofilament Levels of Multiple Sclerosis Patients Before and After Treatment with First-Line Immunomodulatory Therapies (2020) (12)
Protease-resistant SOD1 aggregates in amyotrophic lateral sclerosis demonstrated by paraffin-embedded tissue (PET) blot (2014) (12)
Detection of intrathecal immunoglobulin G synthesis by capillary isoelectric focusing immunoassay in oligoclonal band negative multiple sclerosis (2016) (12)
Role of glial 14-3-3 gamma protein in autoimmune demyelination (2015) (12)
Proteomic analysis reveals a biosignature of decreased synaptic protein in cerebrospinal fluid of major depressive disorder (2020) (12)
Clinico-genetic findings in 509 frontotemporal dementia patients (2021) (11)
Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum NfL and pNfH: A Longitudinal Multicentre Study (2021) (11)
The Use of S100B and Tau Protein Concentrations in the Cerebrospinal Fluid for the Differential Diagnosis of Bacterial Meningitis: A Retrospective Analysis (2011) (11)
Sharpening the boundaries of Parkinson-associated dementia: recommendation for a neuropsychological diagnostic procedure (2010) (11)
Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome (2022) (11)
Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of Aβ species (2018) (11)
Serum neurofilament light chain (NFL) remains unchanged during electroconvulsive therapy (2019) (10)
CSF Ubiquitin Levels Are Higher in Alzheimer’s Disease than in Frontotemporal Dementia and Reflect the Molecular Subtype in Prion Disease (2020) (10)
ERK2 is increased in cerebrospinal fluid of Creutzfeldt-Jakob disease patients. (2010) (10)
Elevated glial fibrillary acidic protein levels in the cerebrospinal fluid of patients with narcolepsy. (2013) (10)
Unraveling corticobasal syndrome and alien limb syndrome with structural brain imaging (2019) (10)
[Current cerebrospinal fluid diagnostics for pathogen-related diseases]. (2013) (10)
[Cerebrospinal fluid-based diagnostics of CT-negative subarachnoid haemorrhage]. (2010) (10)
Varicella zoster virus-induced neurological disease after COVID-19 vaccination: a retrospective monocentric study (2021) (10)
Optical coherence tomography-based assessment of retinal vascular pathology in cerebral small vessel disease (2020) (9)
The role ANCA and anti-GBM antibodies in pulmonary-renal syndrome due to Wegener's granulomatosis. (2007) (9)
Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration (2021) (9)
Association of Lumbar MRI Findings with Current and Future Back Pain in a Population-based Cohort Study (2021) (9)
Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview (2021) (9)
The applause sign in frontotemporal lobar degeneration and related conditions (2018) (9)
Cerebrospinal Fluid Levels of Prodynorphin‐Derived Peptides are Decreased in Huntington's Disease (2020) (9)
Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in C9orf72 expansion carriers in the GENFI cohort (2020) (9)
Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials (2021) (9)
A multi-center study of neurofilament assay reliability and inter-laboratory variability (2020) (9)
Neurochemical dementia diagnostics: assays in CSF and blood (2008) (9)
Relationship between cerebrospinal fluid concentrations of orexin A/hypocretin-1 and body composition in humans (2018) (9)
Hypocretin measurement in an Icelandic foal with narcolepsy. (2009) (9)
A language-based sum score for the course and therapeutic intervention in primary progressive aphasia (2018) (9)
Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study (2020) (9)
Collet-Sicard's syndrome as a result of jugular vein thrombosis (2001) (9)
Disease-Specific Regions Outperform Whole-Brain Approaches in Identifying Progressive Supranuclear Palsy: A Multicentric MRI Study (2017) (8)
Development and Validation of an Ultrasensitive Procalcitonin Sandwich Immunoassay (2017) (8)
Abeta peptide 1-42, Tau protein and S-100B protein level in cerebrospinal fluid of three patients with primary progressive aphasia. (2002) (8)
Differences in Sex Distribution Between Genetic and Sporadic Frontotemporal Dementia (2021) (8)
An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels (2010) (8)
Dipeptide repeat protein and TDP-43 pathology along the hypothalamic–pituitary axis in C9orf72 and non-C9orf72 ALS and FTLD-TDP cases (2020) (8)
FRONTotemporal dementia Incidence European Research Study—FRONTIERS: Rationale and design (2021) (8)
Serum neuro ﬁ lament light chain No clear relation to cognition and neuropsychiatric symptoms in stable MS (8)
Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease (2021) (8)
Serum Beta‐Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181 (2022) (8)
Protein Binding Partners of Dysregulated miRNAs in Parkinson’s Disease Serum (2021) (7)
The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort (2021) (7)
Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis (2019) (7)
Motor speech disorders in the nonfluent, semantic and logopenic variants of primary progressive aphasia (2021) (7)
Microchip electrophoresis, with respect to "profiling of Aβ peptides in the cerebrospinal fluid of patients with Alzheimer's disease". (2012) (7)
MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia (2021) (7)
Network Localization of Alien Limb in Patients with Corticobasal Syndrome (2020) (7)
Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis (2022) (7)
Disease-related cortical thinning in presymptomatic granulin mutation carriers (2020) (7)
Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy (2021) (7)
Disentangling brain functional network remodeling in corticobasal syndrome – A multimodal MRI study (2019) (7)
Different Inflammatory Signatures in Alzheimer’s Disease and Frontotemporal Dementia Cerebrospinal Fluid (2021) (6)
[Biomarkers for dementia and other neurodegenerative diseases : Current developments]. (2016) (6)
Lithium decreases secretion of Abeta1-42 and C-truncated species Abeta1-37/38/39/40 in chicken telencephalic cultures but specifically increases intracellular Abeta1-38. (2004) (6)
Glial fibrillary acidic protein and protein S-100B: Different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer' s disease and Creutzfeldt-Jakob disease (2009) (6)
Association of cerebrospinal fluid kappa free light chains with the intrathecal polyspecific antiviral immune response in multiple sclerosis. (2019) (6)
Detection and Differentiation of Threonine- and Tyrosine-Monophosphorylated Forms of ERK1/2 by Capillary Isoelectric Focusing-Immunoassay (2015) (6)
Creutzfeldt-Jakob Disease and Homocysteine Levels in Plasma and Cerebrospinal Fluid (2005) (5)
Ongoing challenges in unravelling the association between COVID-19 and Guillain-Barré syndrome (2021) (5)
[Genetic architecture of amyotrophic lateral sclerosis and frontotemporal dementia : Overlap and differences]. (2017) (5)
Genetic variants in PSEN2 and correlation to CSF β-amyloid42 levels in AD (2012) (5)
Stress cardiomyopathy associated with the first manifestation of multiple sclerosis: a case report (2020) (5)
The multifaceted role of neurofilament light chain protein in non-primary neurological diseases (2022) (5)
Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort (2021) (5)
Comparative analysis of machine learning algorithms for multi-syndrome classification of neurodegenerative syndromes (2021) (5)
On‐line capillary electrophoresis derivatization method for high sensitivity analysis of ubiquitin in filtered cerebrospinal fluid (2013) (5)
Production of endogenous interferon-α and β in patients with multiple sclerosis (1998) (5)
Global network structure and local transcriptomic vulnerability shape atrophy in sporadic and genetic behavioral variant frontotemporal dementia (2021) (4)
Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia (2022) (4)
S-ketamine induces acute changes in the proteome of the mouse amygdala. (2020) (4)
Cerebrospinal fluid analysis for diagnosis of noninflammatory, dementive and psychiatric diseases (2009) (4)
53 One-year treatment with clevudine demonstrated significant viral suppression and biochemical improvement (2006) (4)
Cerebrospinal fluid and serum NT-proBNP concentrations in children with epilepsy (2009) (4)
Differential Expression of Serum Extracellular Vesicle miRNAs in Multiple Sclerosis: Disease-Stage Specificity and Relevance to Pathophysiology (2022) (4)
Free caspase activity in CSF of patients with dementia (2009) (4)
Erratum to: Different CSF β-amyloid processing in Alzheimer’s and Creutzfeldt–Jakob disease (2011) (4)
Chromogranin A levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis (2018) (4)
Serum glial fibrillary acidic protein indicates memory impairment in patients with chronic heart failure (2022) (4)
Moral judgment in patients with behavioral variant of frontotemporal dementia and amyotrophic lateral sclerosis: no impairment of the moral position, but rather its execution (2018) (4)
Predicting disease progression in behavioral variant frontotemporal dementia (2021) (3)
Blood β-Synuclein and Neurofilament Light Chain During the Course of Prion Disease (2022) (3)
Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis (2020) (3)
CSF levels of SNAP-25 are increased early in Creutzfeldt-Jakob and Alzheimer’s disease (2022) (3)
Relationship of serum beta‐synuclein with blood biomarkers and brain atrophy (2022) (3)
"Microchip Electrophoresis," with Respect to "Profiling of Aβ Peptides in the Cerebrospinal Fluid of Patients with Alzheimer's Disease". (2018) (3)
Recent biomarker approaches in the diagnosis of frontotemporal lobar degeneration/Neurochemische Ansätze in der Diagnose der Frontotemporalen Lobärdegeneration (2012) (3)
Neurofilament light chain: A novel blood biomarker in patients with ataxia telangiectasia. (2021) (3)
Different binding pattern of antibodies to prion protein on lymphocytes from patients with sporadic Creutzfeldt–Jakob disease (2003) (3)
Plasma Amyloid‐BetaPeptides in Acute Cerebral Ischemia: A Pilot Study (2012) (3)
Lipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis (2020) (3)
Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer’s disease (2022) (3)
TCT-4 Reduction of stroke with use of the double-filter cerebral embolic protection device in patients undergoing transfemoral aortic valve replacement with self-expandable, mechanically implantable and balloon-expandable aortic valves (2018) (3)
Validation of a multiplexing technique to determine the intrathecal, polyspecific antiviral immune response in multiple sclerosis (2016) (2)
[Imipenem in the treatment of patients with severe surgical infection]. (1992) (2)
Author Correction: A ferroptosis–based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis (2020) (2)
Tau, phospho-tau and S-100B protein in cerebrospinal fluid of children with multiple sclerosis (2004) (2)
Resting-State Alterations in Behavioral Variant Frontotemporal Dementia are Related to the Distribution of Monoamine and GABA Neurotransmitter Systems (2021) (2)
Selective reduction of amyloid β42 discriminates Alzheimer’s disease from Huntington’s disease: indication for distinct pathological events in amyloid β peptide aggregation (2006) (2)
Comprehensive microRNA expression profiling in cerebrospinal fluid distinguishes between neurological disease classes (2019) (2)
Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients (2022) (2)
Unaltered apoptotic behaviour of mononuclear cells from patients with sporadic Creutzfeldt-Jakob disease (2001) (2)
Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy (2022) (2)
Differential effect of ethanol intoxication on peripheral markers of cerebral injury in murine blunt traumatic brain injury (2021) (2)
Quantitative analysis of regional distribution of tau pathology with 11C-PBB3-PET in a clinical setting (2022) (2)
Prodynorphin and Proenkephalin in Cerebrospinal Fluid of Sporadic Creutzfeldt–Jakob Disease (2022) (2)
Author Correction: Serum GFAP as a biomarker for disease severity in multiple sclerosis (2019) (2)
Alpha-synuclein is present in dental calculus but not altered in Parkinson’s disease patients in comparison to controls (2018) (1)
[Memory clinics in Germany-structural requirements and areas of responsibility]. (2020) (1)
Markers of vitamin B12 status in relation to cerebrospinal fluid biomarkers and cognitive performance (2020) (1)
Neurofilaments in blood (2017) (1)
Genetic variants in presenilins and correlation to amyloid-beta 42 levels in cerebrospinal fluid and diagnosis of Alzheimer's disease (2009) (1)
Neurochemical Monitoring of Traumatic Brain Injury by the Combined Analysis of Plasma Beta-Synuclein, NfL, and GFAP in Polytraumatized Patients (2022) (1)
Data-driven algorithm for the diagnosis of behavioral variant frontotemporal dementia (2019) (1)
THE ROLE OF ANCA AND ANTI-GBM ANTIBODIES (2007) (1)
PS216. Preclinical and clinical assessment of tryptophan catabolites (TRYCATS) as a measure of neuroinflammation and utility in compound screening. (2016) (1)
Glutamate receptor 4 as a fluid biomarker for the diagnosis of psychiatric disorders. (2022) (1)
Visinin-like protein 1 levels in blood and CSF as emerging markers for Alzheimer’s and other neurodegenerative diseases (2022) (1)
Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study (2021) (1)
On Razor's edge: Managing analgosedation during severe anti-NMDA receptor encephalitis (2018) (1)
1180 PROTEOMICS IN CEREBROSPINAL FLUID IN PATIENTS WITH HEPATITIS C VIRUS INFECTION AND NEUROPSYCHIATRIC SYMPTOMS (2011) (1)
Tick-Borne Encephalitis: A Differential Pattern of Intrathecal Humoral Immune Response and Inflammatory Cell Composition Compared with Other Viral CNS Infections (2020) (1)
Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach (2020) (1)
Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington’s and Parkinson’s disease (2022) (1)
Comparison of MRI-based and PET-based image pre-processing for quantification of 11C-PBB3 uptake in human brain. (2021) (1)
Comment: Tau CSF proteins for diagnosis but tau PET imaging for AD diagnosis and staging (2018) (1)
Reply: Adult-onset distal spinal muscular atrophy: a new phenotype associated with KIF5A mutations. (2019) (1)
International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease (2020) (1)
Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer’s Disease (2022) (1)
Subtype and stage inference identifies distinct atrophy patterns in genetic frontotemporal dementia that MAP onto specific MAPT mutations (2020) (1)
Dementia diagnostics 2.0--transfer from research studies into routine clinical practice. (2010) (1)
Association of Serum GFAP with Functional and Neurocognitive Outcome in Sporadic Small Vessel Disease (2022) (1)
[Comments on the article by K. Buch et al. Tau protein: a potential biological marker for early detection of Alzheimer disease. Nervenarzt (1998) 69:379-385]. (1999) (1)
Assessment of Alzheimer's disease risk genes with CSF-biomarker levels (2013) (1)
A one-year longitudinal evaluation of cerebrospinal fluid and blood neurochemical markers in a patient with cryptococcal meningitis complicated by ischemic stroke. (2021) (1)
Imaging of neurodegenerative diseases using Tau PET/CT with [11C]PBB3 in a clinical setting (2019) (0)
GSM1278124: serum_healthy control_15 (2014) (0)
Behavioral variant frontotemporal dementia can be conceptualized and individually predicted with meta-analyses & pattern classification of imaging data (2016) (0)
A12 Mitochondrial proteome analysis of R6/2 mouse brains (2010) (0)
[Gene-specific treatment approaches in Alzheimer's disease and other tauopathies]. (2020) (0)
Quantitative mass spectrometry suggests beta‐synuclein as promising blood marker for synaptic degeneration in Alzheimer's disease (2020) (0)
MRI AS OBJECTIVE FOLLOW-UP PARAMETER IN PATIENTS OF PRIMARY PROGRESSIVE APHASIAS (2019) (0)
TCT-35 Cerebral embolic protection during transfemoral aortic valve replacement reduces death and stroke compared to unprotected procedure in all subgroups (2017) (0)
EPV 2. Spreading patterns of behavioral variant frontotemporal dementia: Analysis of longitudinal in vivo diffusion tensor imaging data (2016) (0)
GSE52917: Early pre-symptomatic and progressive signatures of non-coding RNAs in ALS patients and mutation carriers (2014) (0)
GSM1278156: serum_sALS patient_12 (2014) (0)
GSM1278144: serum_ALS mutation carrier_12 (2014) (0)
GSM1278123: serum_healthy control_14 (2014) (0)
GSM1278158: serum_sALS patient_14 (2014) (0)
Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials (2021) (0)
Investigating brain structure in different FTLD subtypes using voxel-based morphometry – Data from the multicentric FTLD consortium’s study Germany (2014) (0)
Investigating progressive supranuclear palsy using VBM and SVM classification (2016) (0)
GSM1278117: serum_healthy control_8 (2014) (0)
GSM1278138: serum_ALS mutation carrier pool 2 (2014) (0)
Method of diagnosing Alzheimer's disease (2012) (0)
Moyamoya disease precipitating Sydenham's chorea (2009) (0)
GSM1278134: serum_ALS mutation carrier_2 (2014) (0)
GSM1278126: serum_healthy control_17 (2014) (0)
DELETION OF 14-3-3GAMMA EXACERBATES DISEASE IN MOUSE MODELS OF NEURODEGENERATIVE PROTEINOPATHY (2014) (0)
Support vector machine classification enables detection of primary progressive aphasia subtypes with MRI (2015) (0)
Evaluation of Visual Rating Scales for MRI Supported Diagnosis of Frontotemporal Lobar Degeneration (2012) (0)
GSM1278161: serum_sALS patient_17 (2014) (0)
GSM1278150: serum_sALS patient_6 (2014) (0)
GSM1278159: serum_sALS patient_15 (2014) (0)
B32 Alterations in Mitochondrial Proteome of Brain and Skeletal Muscle in Two Transgenic HD Mouse Models do not Reflect Mitochondrial Respiratory Activity (2014) (0)
Moyamoya disease precipitating Sydenham's chorea in a 19‐year‐old Caucasian woman (2009) (0)
CONCEPTUALIZING AND INDIVIDUALLY PREDICTING BEHAVIOURAL VARIANT FRONTOTEMPORAL DEMENTIA WITH META-ANALYSES AND PATTERN CLASSIFICATION OF IMAGING DATA (2016) (0)
Two distinct molecular patterns of TDP‐43 pathology in cases with Alzheimer’s disease pathology (2020) (0)
GSM1278110: serum_healthy control_1 (2014) (0)
Novel CSF Biomarkers of Disease Progression of Amyotrophic Lateral Sclerosis (2011) (0)
Clinical Study Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in (2011) (0)
Neurofilament light chain: a biomarker for disease onset and survival in genetic frontotemporal dementia (2016) (0)
Contents Vol. 19, 2005 (2005) (0)
Aβ oligomerization is associated with the generation of a typical peptide fragment 1 fingerprint . 2 3 (2017) (0)
Correction to: Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia (2020) (0)
Advancing mechanistic understanding and biomarker development in amyotrophic lateral sclerosis (2021) (0)
Measurement of ERK1/2 isoform distribution in peripheral blood mononuclear cells derived from whole blood from patients with different neuropsychiatric disorders (2015) (0)
Classifying primary progressive aphasias individually with support vector machine approaches in MRI data (2016) (0)
ROLE OF FREE AND EXOSOMAL TDP-43 AS A DIAGNOSTIC TOOL IN NEURODEGENERATIVE DISEASES (2014) (0)
1217 VIROLOGICAL ANALYSIS OF HCV GENOTYPE 1 PATIENT SAMPLES FROM THE PROTON STUDY (2012) (0)
Serum GFAP as a biomarker for disease severity in multiple sclerosis (2018) (0)
Characterizing neurodegeneration in progressive supranuclear palsy using VBM and SVM classification (2016) (0)
GSM1278135: serum_ALS mutation carrier_3 (2014) (0)
Therapeutic approaches in frontotemporal lobar degeneration – anti-tau therapy strategy in primary progressive aphasia (2017) (0)
TDP-43 and beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration (2009) (0)
Glial Fibrillary Acidic Protein in Cerebrospinal Fluid of Nusinersen-Treated Patients with Spinal Muscular Atrophy (2021) (0)
GSM1278149: serum_sALS patient_5 (2014) (0)
Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia (2018) (0)
GSM1278129: serum_fALS patient_3 (2014) (0)
GSM1278140: serum_ALS mutation carrier_8 (2014) (0)
GSM1278141: serum_ALS mutation carrier pool 4 (2014) (0)
Trajectory of apathy, cognition and neural correlates in the decades before symptoms in frontotemporal dementia (2020) (0)
New trends in classification, monitoring and management of neurological diseases (2003) (0)
Reporting Cerebrospinal Fluid Data: Knowledge Base and Interpretation Software* (2004) (0)
GSM1278112: serum_healthy control_3 (2014) (0)
Role of glial 14-3-3 gamma protein in autoimmune demyelination (2015) (0)
GSM1278114: serum_healthy control_5 (2014) (0)
Subject Index Vol. 19, 2005 (2005) (0)
GSM1278155: serum_sALS patient_11 (2014) (0)
GSM1278113: serum_healthy control_4 (2014) (0)
GSM1278127: serum_fALS patient pool 1 (2014) (0)
GSM1278147: serum_sALS patient_3 (2014) (0)
Increased neurofilament light chain correlates with decreased white matter integrity in presymptomatic and symptomatic granulin carriers (2016) (0)
Protease-resistant SOD1 aggregates in amyotrophic lateral sclerosis demonstrated by paraffin-embedded tissue (PET) blot (2014) (0)
Hierarchical involvement of molecular players in human neocortex in the course of preclinical and symptomatic Alzheimer’s disease (2020) (0)
GSM1278160: serum_sALS patient_16 (2014) (0)
Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression (2017) (0)
Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis (2019) (0)
DIFFERENTIAL SIALYLATION OF SERPIN A1, DETECTED BY NANOSCALE CAPILLARY ISOELECTRIC FOCUSING IN CEREBROSPINAL FLUID, AS AN EARLY DIAGNOSTIC MARKER OF PARKINSON’S DISEASE DEMENTIA (2014) (0)
GSM1278139: serum_ALS mutation carrier pool 3 (2014) (0)
Differential effect of ethanol intoxication on peripheral markers of cerebral injury in murine blunt TBI (2020) (0)
GSM1278111: serum_healthy control_2 (2014) (0)
GSM1278128: serum_fALS patient pool 2 (2014) (0)
GSM1278143: serum_ALS mutation carrier_11 (2014) (0)
DIADEM / Participants Directory (2004) (0)
GSM1278136: serum_ALS mutation carrier_4 (2014) (0)
Cerebellar and subcortical atrophy contribute to psychiatric symptoms in frontotemporal dementia (2021) (0)
O2-02-05 Surface enhanced laser desorption/ionization time-of-flight mass spectrometry for the differential diagnosis of Creutzfeld-Jakob disease (2004) (0)
The potential role of neuroinflammation and synaptic plasticity for neuropsychiatric symptoms (2020) (0)
GSM1278125: serum_healthy control_16 (2014) (0)
Voxel-based morphometry in primary progressive aphasia and its subtypes–data from the multicentric FTLD consortium’s study Germany (2014) (0)
GSM1278137: serum_ALS mutation carrier_5 (2014) (0)
Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldt–Jakob disease (2010) (0)
GSM1278119: serum_healthy control_10 (2014) (0)
lyl sulfones for dual site-speci fi c labelling of proteins and cyclic peptides † (2016) (0)
Laboratory Diagnosis of Subarachnoid Haemorrhage (2015) (0)
Atlas-based volumetric MRI analysis of c9orf72 mutation carriers (2016) (0)
GSM1278162: serum_sALS patient_18 (2014) (0)
SERUM GLIAL FIBRILLARY ACIDIC PROTEIN INDICATES COGNITIVE DEFICITS IN PATIENTS WITH HEART FAILURE - FINDINGS FROM THE COGNITION.MATTERS-HF STUDY (2022) (0)
GSM1278118: serum_healthy control_9 (2014) (0)
Motor speech disorders in the nonfluent, semantic and logopenic variants of primary progressive aphasia. Supplementary data: Motor speech characterization per participant (2021) (0)
Increased NF-L levels in the TDP-43G298S ALS mouse model resemble NF-L levels in ALS patients (2022) (0)
White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation (2018) (0)
The Free Cued Selective Reminding Test detects episodic memory impairment in the presymptomatic period of familial frontotemporal dementia within the GENFI cohort (2020) (0)
D04 Blood-CSF barrier function and CSF flow influence CSF biomarkers in huntington’s disease (2018) (0)
Clinical imdications of nucleic acid amdification I I methods for the diagnosis of viral infections of the nervous system (1996) (0)
Dysregulation of a novel miR-1825/TBCB/TUBA4A pathway in sporadic and familial ALS (2018) (0)
GSM1278157: serum_sALS patient_13 (2014) (0)
GSM1278153: serum_sALS patient_9 (2014) (0)
FACIAL PERCEPTION OF TRUSTWORTHINESS IN FRONTOTEMPORAL DEMENTIA (2014) (0)
Special Issue CCA for the proceedings of the 2nd symposium of the Society of CSF analysis and clinical neurochemistry. (2019) (0)
GSM1278151: serum_sALS patient_7 (2014) (0)
O4-04-03 Lithium decreases secretion of Abeta 1–42 and C-truncated species Abeta 1-37/38/39/40 in chicken telencephalic cultures but specifically increases intracellular Abeta 1–38 (2004) (0)
GSM1278145: serum_sALS patient_1 (2014) (0)
GSM1278116: serum_healthy control_7 (2014) (0)
Neurochemical markers in the differential diagnosis of primary progressive aphasias: Data from the German FTLD consortium (2016) (0)
GSM1278132: serum_fALS patient_6 (2014) (0)
GSM1278142: serum_ALS mutation carrier_10 (2014) (0)
TCT-588 Have patients with a history of cerebral events a higher risk of periprocedural stroke during protected transfemoral aortic valve implantation with use of a double filter cerebral embolic protection device? Results of a large all comers population (2018) (0)
GSM1278130: serum_fALS patient_4 (2014) (0)
GSM1278122: serum_healthy control_13 (2014) (0)
The inner fl uctuations of the brain in presymptomatic Frontotemporal Dementia : The chronnectome fi ngerprint (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Markus Otto?

Markus Otto is affiliated with the following schools:

University of Ulm

Markus Otto's Academic­Influence.com Rankings

Why Is Markus Otto Influential?

Markus Otto's Published Works

Published Works

What Schools Are Affiliated With Markus Otto?

Markus Otto's AcademicInfluence.com Rankings